The FDA Has Granted RMAT Designation To The Combination Therapy Of Affimed's Acimtamig And Artiva Biotherapeutic's AlloNK (AB101) For Relapsed Or Refractory Hodgkin Lymphoma
The FDA Has Granted RMAT Designation To The Combination Therapy Of Affimed's Acimtamig And Artiva Biotherapeutic's AlloNK (AB101) For Relapsed Or Refractory Hodgkin Lymphoma
FDA已授予Affimed的Acimtamig与Artiva生物治疗的AlloNk（AB101）组合疗法针对复发或难治性霍奇金淋巴瘤的RMAt认证。
The combination is being evaluated in the on-going LuminICE-203 multicenter, multi-cohort phase 2 trial.
该组合疗法正在进行的LuminICE-203多中心、多队列第二期临床试验中进行评估。
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
资讯热榜
更新时间